CN113729221A - 一种抗肿瘤枸杞薏米复合酵素的制作工艺 - Google Patents
一种抗肿瘤枸杞薏米复合酵素的制作工艺 Download PDFInfo
- Publication number
- CN113729221A CN113729221A CN202111055799.0A CN202111055799A CN113729221A CN 113729221 A CN113729221 A CN 113729221A CN 202111055799 A CN202111055799 A CN 202111055799A CN 113729221 A CN113729221 A CN 113729221A
- Authority
- CN
- China
- Prior art keywords
- fermentation
- tumor
- coix seed
- wolfberry
- preparation process
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000790 Enzymes Proteins 0.000 title claims abstract description 35
- 102000004190 Enzymes Human genes 0.000 title claims abstract description 35
- 244000077995 Coix lacryma jobi Species 0.000 title claims abstract description 28
- 239000002131 composite material Substances 0.000 title claims abstract description 21
- 235000015468 Lycium chinense Nutrition 0.000 title claims abstract description 18
- 230000000259 anti-tumor effect Effects 0.000 title claims abstract description 18
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- 235000015459 Lycium barbarum Nutrition 0.000 title claims abstract description 11
- 244000241838 Lycium barbarum Species 0.000 title claims 4
- 238000000855 fermentation Methods 0.000 claims abstract description 53
- 230000004151 fermentation Effects 0.000 claims abstract description 53
- 239000000758 substrate Substances 0.000 claims abstract description 30
- 235000017784 Mespilus germanica Nutrition 0.000 claims abstract description 20
- 244000182216 Mimusops elengi Species 0.000 claims abstract description 20
- 235000000560 Mimusops elengi Nutrition 0.000 claims abstract description 20
- 235000007837 Vangueria infausta Nutrition 0.000 claims abstract description 20
- 239000006041 probiotic Substances 0.000 claims abstract description 17
- 235000018291 probiotics Nutrition 0.000 claims abstract description 17
- 238000011081 inoculation Methods 0.000 claims abstract description 16
- 239000011550 stock solution Substances 0.000 claims abstract description 11
- 238000001914 filtration Methods 0.000 claims abstract description 9
- 150000001875 compounds Chemical class 0.000 claims abstract description 7
- 230000000529 probiotic effect Effects 0.000 claims abstract description 7
- 240000005979 Hordeum vulgare Species 0.000 claims abstract description 6
- 235000007340 Hordeum vulgare Nutrition 0.000 claims abstract description 6
- 238000000034 method Methods 0.000 claims abstract description 6
- 238000004537 pulping Methods 0.000 claims abstract description 6
- 230000001954 sterilising effect Effects 0.000 claims abstract description 6
- 238000005303 weighing Methods 0.000 claims abstract description 6
- 238000007865 diluting Methods 0.000 claims abstract description 4
- 229940088598 enzyme Drugs 0.000 claims description 31
- 241000186018 Bifidobacterium adolescentis Species 0.000 claims description 5
- 240000001046 Lactobacillus acidophilus Species 0.000 claims description 5
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims description 5
- 244000199885 Lactobacillus bulgaricus Species 0.000 claims description 5
- 235000013960 Lactobacillus bulgaricus Nutrition 0.000 claims description 5
- 241000194020 Streptococcus thermophilus Species 0.000 claims description 5
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims description 5
- 229940004208 lactobacillus bulgaricus Drugs 0.000 claims description 5
- 241000894006 Bacteria Species 0.000 claims description 4
- 108010059892 Cellulase Proteins 0.000 claims description 4
- 108010059820 Polygalacturonase Proteins 0.000 claims description 4
- 229940106157 cellulase Drugs 0.000 claims description 4
- 108010093305 exopolygalacturonase Proteins 0.000 claims description 4
- 240000007594 Oryza sativa Species 0.000 claims description 3
- 235000007164 Oryza sativa Nutrition 0.000 claims description 3
- 235000009566 rice Nutrition 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 abstract description 15
- 244000241872 Lycium chinense Species 0.000 abstract description 14
- 230000002401 inhibitory effect Effects 0.000 abstract description 7
- 201000011510 cancer Diseases 0.000 abstract description 6
- 230000036541 health Effects 0.000 abstract description 3
- 230000009286 beneficial effect Effects 0.000 abstract description 2
- 230000000694 effects Effects 0.000 description 8
- 150000004676 glycans Chemical class 0.000 description 6
- 229920001282 polysaccharide Polymers 0.000 description 6
- 239000005017 polysaccharide Substances 0.000 description 6
- 229920002444 Exopolysaccharide Polymers 0.000 description 5
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 235000007354 Coix lacryma jobi Nutrition 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000005360 mashing Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
- A23L7/10—Cereal-derived products
- A23L7/104—Fermentation of farinaceous cereal or cereal material; Addition of enzymes or microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/113—Acidophilus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/123—Bulgaricus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/21—Streptococcus, lactococcus
- A23V2400/249—Thermophilus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/513—Adolescentes
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种抗肿瘤枸杞薏米复合酵素的制作工艺,主要涉及复合酵素领域。包括以下步骤,步骤一:将枸杞和薏米通过称重、打浆、酶解、过滤、杀菌的预处理得到发酵底物;步骤二:采用一定菌种比例的益生菌对所述发酵底物进行接种发酵;步骤三:以5%‑7%的所述益生菌接种量、8%‑10%的所述发酵底物浓度发酵6d‑8d的时间;步骤四:发酵结束,发酵液经低温离心、过滤,得酵素原液;步骤五:将所述酵素原液稀释一定的浓度得到复合酵素。本发明的有益效果在于:能制作出具有抑制肿瘤和癌细胞的枸杞薏米复合酵素,更加在满足人们日常保健需求的同时,还能降低人们罹患肿瘤和癌症的风险。
Description
技术领域
本发明涉及复合酵素领域,具体是一种抗肿瘤枸杞薏米复合酵素的制作工艺。
背景技术
复合酵素是在人身体内起反应作用的,除了先天性原因缺酵素,导致人的生理机能不正常外,人从年轻到衰老,体内的酵素也从旺盛到不足,摄入的养料不容易消化吸收,依靠摄取养料来合成酵素的能力下降,造成恶性循环,新陈代谢便趋于缓慢,容易疲劳,一旦患病就不易痊愈。为了延缓衰老,防病治病,增强体质,需要补充多种的酵素。
当今社会,肿瘤和癌症是最为致命的疾病之一,虽然市面上的复合酵素产品较多,但基本只起到基本的保健作用,并不能对肿瘤起到有效的抑制作用。
枸杞具有丰富的营养价值和特殊的医疗保健作用,具有抑制肿瘤作用的成分,枸杞中的枸杞多糖是一种水溶性多糖,是枸杞中最主要的活性成分,能够调节机体免疫功能、有效抑制肿瘤生长和细胞突变。
薏仁中的薏仁油、薏仁酯等成分有抗肿瘤作用,如抑制癌细胞转移和增生、诱导癌细胞凋亡、抑制肿瘤血管形成且能提高放射时的敏感性等。
发明内容
本发明的目的在于提供一种抗肿瘤枸杞薏米复合酵素的制作工艺,它能制作出具有抑制肿瘤和癌细胞的枸杞薏米复合酵素,更加在满足人们日常保健需求的同时,还能降低人们罹患肿瘤和癌症的风险。
本发明为实现上述目的,通过以下技术方案实现:
一种抗肿瘤枸杞薏米复合酵素的制作工艺,包括以下步骤,
步骤一:将枸杞和薏米通过称重、打浆、酶解、过滤、杀菌的预处理得到发酵底物;
步骤二:采用一定菌种比例的益生菌对所述发酵底物进行接种发酵;
步骤三:以5%-7%的所述益生菌接种量、8%-10%的所述发酵底物浓度发酵6d-8d的时间;
步骤四:发酵结束,发酵液经低温离心、过滤,得酵素原液;
步骤五:将所述酵素原液稀释一定的浓度得到复合酵素。
进一步的,所述步骤一中采用一定比例的纤维素酶和果胶酶对米浆进行酶解。
进一步的,所述益生菌的菌种组成为保加利亚乳杆菌、嗜热链球菌、嗜酸乳杆菌、青春双歧杆菌。
对比现有技术,本发明的有益效果在于:
通过本发明的制作工艺,以枸杞和薏米为原材料,利用枸杞具有抑制肿瘤作用的成分和枸杞中能够调节机体免疫功能、有效抑制肿瘤生长和细胞突变的活性成分,将枸杞和薏米这两种材料同时发酵制成的发酵底物再稀释一定浓度后得到枸杞薏米复合酵素,可利用枸杞薏米复合酵素开发具有抗肿瘤功能的保健食品,从而被大众长期食用后起到制癌细胞转移和增生、诱导癌细胞凋亡、抑制肿瘤血管形成且能提高放射时的敏感性等功效,降低人们罹患肿瘤和癌症的风险。
附图说明
附图1是本发明的接种量对胞外多糖含量影响的折线图。
附图2是本发明的底物浓度对胞外多糖含量影响的折线图。
附图3是本发明的菌种比例对胞外多糖影响的折线图。
附图4是本发明的发酵时间对残糖量影响的折线图。
附图5是本发明的发酵时间对胞外多糖含量影响的折线图。
附图6是本发明的底物浓度对残糖量影响的折线图。
附图7是本发明的枸杞薏米复合酵素抗肿瘤能力的折线图。
附图8是本发明的人非小细胞肺癌细胞图。
具体实施方式
下面结合具体实施例,进一步阐述本发明。应理解,这些实施例仅用于说明本发明而不用于限制本发明的范围。此外应理解,在阅读了本发明讲授的内容之后,本领域技术人员可以对本发明作各种改动或修改,这些等价形式同样落于本申请所限定的范围。
本发明所述是一种抗肿瘤枸杞薏米复合酵素的制作工艺,包括以下步骤,
步骤一:将枸杞和薏米通过称重、打浆、酶解、过滤、杀菌的预处理得到发酵底物;
步骤二:采用一定菌种比例的益生菌对所述发酵底物进行接种发酵;
步骤三:以5%-7%的所述益生菌接种量、8%-10%的所述发酵底物浓度发酵6d-8d的时间;
步骤四:发酵结束,发酵液经低温离心、过滤,得酵素原液;
步骤五:将所述酵素原液稀释一定的浓度得到复合酵素。
优选的,所述步骤一中采用一定比例的纤维素酶和果胶酶对米浆进行酶解。
优选的,所述益生菌的菌种组成为保加利亚乳杆菌、嗜热链球菌、嗜酸乳杆菌、青春双歧杆菌。
实施例:(一)枸杞薏米复合酵素最佳制作工艺的确定
1.实验预处理,
(1)称重、打浆:将枸杞和薏米称重,按料水质量比1:10加水,100℃浸泡30min后用高速组织捣碎机打浆。
(2)酶解:采用纤维素酶和果胶酶(酶活比1:1)对枸杞薏米浆进行酶解,酶添加量800U/g,酶解温度55℃,酶解时间120min,酶解结束后90℃灭酶10min,酶解液经400目筛网过滤即得枸杞提液。
(2)杀菌:枸杞薏米水提液分装后经95℃杀菌15min作为发酵底物。
2.枸杞薏米复合酵素最佳工艺的制备,
采用益生菌(保加利亚乳杆菌、嗜热链球菌、嗜酸乳杆菌、青春双歧杆菌)进行接种发酵,以胞外多糖含量、残糖量作为评价指标。通过设置菌种比例和发酵底物浓度,将益生菌按照不同的总接种量接种到发酵底物中,在37℃下静置发酵后确定最佳接种量;制备不同浓度的发酵底物,将益生菌按照总接种量10%等比例添加到发酵底物中,静置发酵后确定最佳底物浓度;调整发酵底物浓度为10%,总接种量10%,将益生菌按照不同菌种比例接种到发酵底物中,在37℃下静置发酵后确定最佳菌种比例;设发酵底物浓度10%,将4种益生菌按照总接种量10%的比例接种到发酵底物中,37℃条件下静置发酵,考察不同发酵时间对发酵液中胞外多糖含量和残糖量的影响,确定最佳发酵时间。在单因素试验的基础上,采用正交试验的方法,研究益生菌发酵枸杞薏米酵素最佳发酵工艺。选取接种量、发酵底物、菌种比例和发酵时间4个因素,每个因素取3个水平,采用L9(34)正交试验表,以胞外多糖含量为评价指标。发酵结束,发酵液经低温离心,过滤,得酵素原液。
(二)对枸杞薏米酵素抗肿瘤的能力进行分析
依据抑制率=(对照组平均吸光度值-加药组平均吸光度值))/对照组平均吸光度值×100%这个公式,对细胞存活率进行测定。将样品组分别按浓度梯度为0.2mg/mL,2mg/mL,20mg/mL从左至右,从上至下依次加入,对照组(即只加细胞不加药物)也如此,并于加MTT前取样镜检。
将各项实验数据统计到下列表格中,
(一)单因素结果
1.接种量
2.发酵底物浓度
3.菌种比例
4.发酵时间
(二)正交试验
1.L9(34)正交实验表
2.枸杞薏米复合酵素发酵工艺正交实验结果
3.正交试验方差分析表(α=0.05)
通过上述实验数据表格,并结合附图1-6,以胞外多糖的含量为评价指标,通过单因素实验和正交试验确定发酵底物浓度9%、接种量6%、菌种比例(保加利亚乳杆菌:嗜热链球菌:嗜酸乳杆菌:青春双歧杆菌)为1:1:2:2、发酵时间为6d为最佳发酵工艺条件,在此条件下制备的枸杞薏米复合酵素原液胞外多糖含量为0.472mg/ml。
(三)枸杞薏米复合酵素抗肿瘤活性测定
平行组:
根据上述枸杞薏米复合酵素抗肿瘤活性测定的数据得出发酵底物稀释不同浓度的抗肿瘤能力,研究结果表明,表明枸杞薏米复合酵素原液具有抗肿瘤的能力且在稀释浓度梯度为10-3时,其抗肿瘤能力最大。
本实施例为最佳制作工艺,并不是唯一制作工艺,即使在材料配比上有所偏差,只要是采用本发明的方法制备枸杞薏米复合酵素的,均属于本发明的保护范围。
Claims (3)
1.一种抗肿瘤枸杞薏米复合酵素的制作工艺,其特征在于:包括以下步骤,
步骤一:将枸杞和薏米通过称重、打浆、酶解、过滤、杀菌的预处理得到发酵底物;
步骤二:采用一定菌种比例的益生菌对所述发酵底物进行接种发酵;
步骤三:以5%-7%的所述益生菌接种量、8%-10%的所述发酵底物浓度发酵6d-8d的时间;
步骤四:发酵结束,发酵液经低温离心、过滤,得酵素原液;
步骤五:将所述酵素原液稀释一定的浓度得到复合酵素。
2.根据权利要求1所述一种抗肿瘤枸杞薏米复合酵素的制作工艺,其特征在于:所述步骤一中采用一定比例的纤维素酶和果胶酶对米浆进行酶解。
3.根据权利要求1所述一种抗肿瘤枸杞薏米复合酵素的制作工艺,其特征在于:所述益生菌的菌种组成为保加利亚乳杆菌、嗜热链球菌、嗜酸乳杆菌、青春双歧杆菌。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111055799.0A CN113729221A (zh) | 2021-09-09 | 2021-09-09 | 一种抗肿瘤枸杞薏米复合酵素的制作工艺 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111055799.0A CN113729221A (zh) | 2021-09-09 | 2021-09-09 | 一种抗肿瘤枸杞薏米复合酵素的制作工艺 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113729221A true CN113729221A (zh) | 2021-12-03 |
Family
ID=78737717
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111055799.0A Pending CN113729221A (zh) | 2021-09-09 | 2021-09-09 | 一种抗肿瘤枸杞薏米复合酵素的制作工艺 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113729221A (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106173613A (zh) * | 2014-10-08 | 2016-12-07 | 中国科学院上海生命科学研究院 | 一种利用益生菌发酵制备果蔬或谷物或药食同源酵素保健食品的方法 |
CN112998170A (zh) * | 2021-04-08 | 2021-06-22 | 东北农业大学 | 一种薏米枸杞复合乳酸发酵饮料的制备方法 |
-
2021
- 2021-09-09 CN CN202111055799.0A patent/CN113729221A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106173613A (zh) * | 2014-10-08 | 2016-12-07 | 中国科学院上海生命科学研究院 | 一种利用益生菌发酵制备果蔬或谷物或药食同源酵素保健食品的方法 |
CN112998170A (zh) * | 2021-04-08 | 2021-06-22 | 东北农业大学 | 一种薏米枸杞复合乳酸发酵饮料的制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105054040B (zh) | 一种益生菌发酵人参的组合物及其制备方法和应用 | |
CN111518720B (zh) | 一株凝结芽孢杆菌(Bacillus coagulans)JA845及其应用 | |
CN110106119B (zh) | 一株分离自母乳的鼠李糖乳杆菌m9及其应用 | |
CN106754619A (zh) | 一种在谷物培养基中添加中药组分促进益生菌生长的方法 | |
CN101275158A (zh) | 优良粪肠球菌的筛选制备方法及其应用 | |
CN106942724A (zh) | 具有调节肠道菌群结构作用的组合物及其制备方法与应用 | |
CN115287239A (zh) | 一株具有体外降解核苷、嘌呤及降尿酸能力的植物乳杆菌及其应用 | |
CN109568518B (zh) | 中药混合菌固体发酵的方法和所得到的发酵中药及其应用 | |
CN106434489A (zh) | 一株高产酒肺炎克雷伯菌株及其应用 | |
CN110755344A (zh) | 灵芝-黄精双向发酵工艺及组合物 | |
CN115895977B (zh) | 一种副干酪乳杆菌及其应用 | |
CN113729221A (zh) | 一种抗肿瘤枸杞薏米复合酵素的制作工艺 | |
CN104644538B (zh) | 黄芩乳酸菌发酵物、含发酵物的化妆品及制备方法和用途 | |
CN111944712A (zh) | 一株具有优良酒精耐受能力的植物乳杆菌和应用 | |
CN111388515A (zh) | 红曲霉液态发酵人参的方法及人参发酵产物和用途 | |
CN111228316A (zh) | 用于改善糖尿病的复合益生菌 | |
CN109456898A (zh) | 一种球毛壳菌右旋糖酐酶的发酵制备及其应用 | |
CN111713659B (zh) | 一种抑制α-葡萄糖苷酶活性羊栖菜制品制备方法和羊栖菜制品 | |
CN112450346B (zh) | 一种无糖啤特果发酵汁制作方法 | |
CN115838661A (zh) | 一种植物乳杆菌扁鹊君18、植物乳杆菌制剂及其应用 | |
CN113648262A (zh) | 化妆品用百合针叶樱桃发酵物及其制备方法 | |
CN113332387A (zh) | 一种玉米须发酵方法 | |
CN115181676B (zh) | 一株通过紫外诱变获得的黄伞菌株及其应用 | |
CN117547572B (zh) | 一种组合物的复合乳酸菌发酵品的制备方法、产品及应用 | |
CN113662894B (zh) | 一种积雪草酶解发酵物及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20211203 |